We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.22B
$73.8M 1.17%
227,800
+16,274
+8% +$4.72M
ILMN icon
27
Illumina
ILMN
$28B
$73.5M 1.17%
227,874
+14,737
+7% +$4.47M
BSX icon
28
Boston Scientific
BSX
$65.7B
$71.4M 1.13%
1,578,621
+158,633
+11% +$6.64M
EXEL icon
29
Exelixis
EXEL
$14.1B
$69.3M 1.1%
3,930,700
+72,000
+2% +$1.22M
BDX icon
30
Becton Dickinson
BDX
$42.9B
$68.5M 1.09%
258,312
+52,464
+25% +$13.1M
CI icon
31
Cigna
CI
$75.1B
$65.3M 1.03%
319,146
+79,852
+33% +$14.6M
MGNX icon
32
MacroGenics
MGNX
$278M
$63.9M 1.01%
5,873,356
+747,792
+15% +$7.4M
TDOC icon
33
Teladoc Health
TDOC
$1.72B
$62.8M 1%
750,045
-389,012
-34% -$29.6M
JAZZ icon
34
Jazz Pharmaceuticals
JAZZ
$15.4B
$56.9M 0.9%
381,303
+51,076
+15% +$6.95M
DHR icon
35
Danaher
DHR
$143B
$56.3M 0.89%
413,517
-5,832
-1% -$737K
AKCA
36
DELISTED
Akcea Therapeutics Inc
AKCA
$53.6M 0.85%
3,162,643
+52,732
+2% +$981K
ARVN icon
37
Arvinas
ARVN
$515M
$51M 0.81%
1,241,903
+435,500
+54% +$12.7M
EW icon
38
Edwards Lifesciences
EW
$49.2B
$47.3M 0.75%
608,229
+24,933
+4% +$1.95M
CNC icon
39
Centene
CNC
$32.9B
$46.6M 0.74%
740,611
+47,697
+7% +$2.59M
BAX icon
40
Baxter International
BAX
$11.5B
$45.1M 0.72%
539,675
+184,107
+52% +$15.2M
CRSP icon
41
CRISPR Therapeutics
CRSP
$4.7B
$44.5M 0.71%
730,462
-106,700
-13% -$5.83M
CRL icon
42
Charles River Laboratories
CRL
$10.6B
$43.2M 0.69%
283,098
+274,798
+3,311% +$38M
INSM icon
43
Insmed
INSM
$23.6B
$37.8M 0.6%
1,583,560
+392,080
+33% +$7.98M
VYGR icon
44
Voyager Therapeutics
VYGR
$189M
$37.7M 0.6%
2,704,283
-400
-0% -$5.81K
HCA icon
45
HCA Healthcare
HCA
$82.2B
$37.3M 0.59%
252,628
+41,246
+20% +$5.54M
SRRK icon
46
Scholar Rock
SRRK
$6.28B
$34.7M 0.55%
2,634,466
+437,366
+20% +$4.2M
SYK icon
47
Stryker
SYK
$123B
$33.9M 0.54%
161,255
-27,029
-14% -$5.61M
QTTB icon
48
Q32 Bio
QTTB
$340M
$33.4M 0.53%
89,562
– –
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$32.2M 0.51%
3,850,000
+200,000
+5% +$1.84M
ZBH icon
50
Zimmer Biomet
ZBH
$17.4B
$32.2M 0.51%
221,483
+72,779
+49% +$10M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.